CervoMed's neflamapimod lowers neuronal damage biomarker at higher exposure in Phase 2a aphasia trial
CRVO•
CRVO•CervoMed presented interim Phase 2a results showing the neuronal damage biomarker remained stable overall among 19 U.S. participants, while higher drug exposure was associated with reductions. The drug was generally well tolerated, and further cohort and clinical results are expected in March 2027.
CervoMed presented interim Phase 2a results for neflamapimod in nonfluent variant primary progressive aphasia at CTAD on Nov. 16, 2026. Among 19 U.S. participants, the neuronal damage biomarker remained stable overall; higher drug exposure was associated with reductions, while lower exposure was associated with increases consistent with untreated disease progression.
Neflamapimod was generally well tolerated, with no new safety signals identified. Higher-dose U.K. cohort biomarker data and clinical results are expected at the AD/PD conference in March 2027.